» Articles » PMID: 16762077

Cationic Polyamines Inhibit Anthrax Lethal Factor Protease

Overview
Journal BMC Pharmacol
Publisher Biomed Central
Specialty Pharmacology
Date 2006 Jun 10
PMID 16762077
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Anthrax is a human disease that results from infection by the bacteria, Bacillus anthracis and has recently been used as a bioterrorist agent. Historically, this disease was associated with Bacillus spore exposure from wool or animal carcasses. While current vaccine approaches (targeted against the protective antigen) are effective for prophylaxis, multiple doses must be injected. Common antibiotics that block the germination process are effective but must be administered early in the infection cycle. In addition, new therapeutics are needed to specifically target the proteolytic activity of lethal factor (LF) associated with this bacterial infection.

Results: Using a fluorescence-based assay to identify and characterize inhibitors of anthrax lethal factor protease activity, we identified several chemically-distinct classes of inhibitory molecules including polyamines, aminoglycosides and cationic peptides. In these studies, spermine was demonstrated for the first time to inhibit anthrax LF with a Ki value of 0.9 +/- 0.09 microM (mean +/- SEM; n = 3). Additional linear polyamines were also active as LF inhibitors with lower potencies.

Conclusion: Based upon the studies reported herein, we chose linear polyamines related to spermine as potential lead optimization candidates and additional testing in cell-based models where cell penetration could be studied. During our screening process, we reproducibly demonstrated that the potencies of certain compounds, including neomycin but not neamine or spermine, were different depending upon the presence or absence of nucleic acids. Differential sensitivity to the presence/absence of nucleic acids may be an additional point to consider when comparing various classes of active compounds for lead optimization.

Citing Articles

Design and use of a novel substrate for simple, rapid, and specific early detection of anthrax infection.

Suryadi K, Shine N PLoS One. 2018; 13(11):e0207084.

PMID: 30412638 PMC: 6226181. DOI: 10.1371/journal.pone.0207084.


Biochemical Features of Beneficial Microbes: Foundations for Therapeutic Microbiology.

Engevik M, Versalovic J Microbiol Spectr. 2017; 5(5).

PMID: 28984235 PMC: 5873327. DOI: 10.1128/microbiolspec.BAD-0012-2016.


Cross-inhibition of pathogenic agents and the host proteins they exploit.

Zilbermintz L, Leonardi W, Tran S, Zozaya J, Mathew-Joseph A, Liem S Sci Rep. 2016; 6:34846.

PMID: 27703274 PMC: 5050486. DOI: 10.1038/srep34846.


Designing inhibitors of anthrax toxin.

Nestorovich E, Bezrukov S Expert Opin Drug Discov. 2014; 9(3):299-318.

PMID: 24447197 PMC: 4307821. DOI: 10.1517/17460441.2014.877884.


Small molecule inhibitors of anthrax lethal factor toxin.

Williams J, Khan A, Cardinale S, Butler M, Bowlin T, Peet N Bioorg Med Chem. 2013; 22(1):419-34.

PMID: 24290062 PMC: 3925373. DOI: 10.1016/j.bmc.2013.11.009.


References
1.
Masuko T, Kuno T, Kashiwagi K, Kusama T, Williams K, Igarashi K . Stimulatory and inhibitory properties of aminoglycoside antibiotics at N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1999; 290(3):1026-33. View

2.
Ezzell Jr J, Abshire T . Serum protease cleavage of Bacillus anthracis protective antigen. J Gen Microbiol. 1992; 138(3):543-9. DOI: 10.1099/00221287-138-3-543. View

3.
Rainey G, Wigelsworth D, Ryan P, Scobie H, Collier R, Young J . Receptor-specific requirements for anthrax toxin delivery into cells. Proc Natl Acad Sci U S A. 2005; 102(37):13278-83. PMC: 1201603. DOI: 10.1073/pnas.0505865102. View

4.
Hoshino K, Momiyama E, Yoshida K, Nishimura K, Sakai S, Toida T . Polyamine transport by mammalian cells and mitochondria: role of antizyme and glycosaminoglycans. J Biol Chem. 2005; 280(52):42801-8. DOI: 10.1074/jbc.M505445200. View

5.
Johnson S, Jung D, Forino M, Chen Y, Satterthwait A, Rozanov D . Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. J Med Chem. 2006; 49(1):27-30. PMC: 3164827. DOI: 10.1021/jm050892j. View